VOR — Vor Biopharma Inc.
Vor Biopharma, Inc. is a clinical-stage biotechnology firm dedicated to developing innovative engineered hematopoietic stem cell (eHSC) therapies for individuals battling cancer. Its lead product candidate, VOR33, is an eHSC therapy currently undergoing Phase 1/2 clinical trials. VOR33 is designed to target acute myeloid leukemia (AML) and various other hematological malignancies. A key feature of VOR33's eHSCs is their engineered absence of the CD33 protein, which is commonly found on AML blood cancer cells. The company's eHSC platform is intended to enable a range of targeted blood cancer treatments, including CAR-T cell therapies, bispecific antibodies, and antibody-drug conjugates. Vor Biopharma has established a partnership with Akron BioProducts for the development and manufacturing of cGMP nucleases. Established in 2015, the company's headquarters are located in Cambridge, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 159
- Website: https://www.vorbio.com
Latest SEC filings for VOR
- S-3ASR — 2026-09-04
- S-3ASR — 2026-09-04
- 10-Q — 2026-08-11
- SCHEDULE 13G/A — 2026-08-07
- SCHEDULE 13G — 2026-08-06
- SCHEDULE 13D/A — 2026-07-21
- 3 — 2026-07-09
- 8-K — 2026-07-07
- 8-K — 2026-06-12
- 8-K — 2026-06-08
Latest VOR news
- — Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire Inc.)
- — Vor Biopharma (NASDAQ:VOR) Shares Up 5.3% – What’s Next?
- — Telitacicept Demonstrates Deep and Durable Minimal Symptom Expression Through 48 Weeks in Generalized Myasthenia Gravis (globenewswire.com)
Educational tool only — not investment advice.